Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
147 results about "Receptor signaling" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Simultaneous stimulation and concentration of cells
InactiveUS6905874B2Maximizes stimulationBiocideImmunoglobulins against cell receptors/antigens/surface-determinantsT cellCells signal
The present invention relates generally to methods for stimulating cells, and more particularly, to a novel method to concentrate and stimulate cells that maximizes stimulation and / or proliferation of such cells. In the various embodiments, cells are stimulated and concentrated with a surface yielding enhanced proliferation, cell signal transduction, and / or cell surface moiety aggregation. In certain aspects methods for stimulating a population of cells such as T-cells, by simultaneous concentration and cell surface moiety ligation are provided by contacting the population of cells with a surface, that has attached thereto one or more agents that ligate a cell surface moiety and applying a force that predominantly drives cell concentration and cell surface moiety ligation, thereby inducing cell stimulation, cell surface moiety aggregation, and / or receptor signaling enhancement. Also provided are methods for producing phenotypically tailored cells, including T-cells for the use in diagnostics, drug discovery, and the treatment of a variety of indications, including cancer, viral infection, and immune related disorders. Compositions of cells having specific phenotypic properties produced by these processes are further provided.
Owner:LIFE TECH CORP
Simultaneous stimulation and concentration of cells
InactiveUS6867041B2Maximizes stimulationCulture processArtificial cell constructsDrug discoveryCells signal
The present invention relates generally to methods for stimulating cells, and more particularly, to a novel method to concentrate and / or stimulate cells that maximizes stimulation and / or proliferation of such cells. In the various embodiments, cells are stimulated and concentrated with a surface yielding enhanced proliferation, cell signal transduction, and / or cell surface moiety aggregation. In certain aspects methods for stimulating a population of cells such as T-cells, by simultaneous concentration and cell surface moiety ligation are provided by contacting the population of cells with a surface, that has attached thereto one or more agents that ligate a cell surface moiety and applying a force that predominantly drives cell concentration and cell surface moiety ligation, thereby inducing cell stimulation, cell surface moiety aggregation, and / or receptor signaling enhancement. Also provided are methods for producing phenotypically tailored cells, including T-cells for the use in diagnostics, drug discovery, and the treatment of a variety of indications, including cancer, viral infection, and immune related disorders. Compositions of cells having specific phenotypic properties produced by these processes are further provided.
Owner:LIFE TECH CORP
Organic Compounds
The invention provides a new method of treating diseases or conditions characterized by reduced dopamine D1 receptor signaling activity, such as Parkinson's disease, depression, and cognitive impairment of schizophrenia, comprising administering an effective amount of a 1,3,5,-substituted, 6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-7-one to a patient in need thereof.
Owner:INTRA CELLULAR THERAPIES INC
Method for identifying modulators of G protein coupled receptor signaling
InactiveUS20070077597A1High affinity bindingAntibacterial agentsAntimycoticsG Protein-Coupled Receptor SignalingPeptide
This invention relates to methods for identifying peptides and other compounds which block or enhance G protein coupled receptor mediated signaling with high affinity and specificity and / or which stabilize a particular conformer of a G protein coupled receptor. Assays, methods of treatment and other methods developed in conjunction with these methods also are disclosed.
Owner:CADEN BIOSCI
Organic compounds
ActiveUS9745300B2Strong therapeutic activitySide effect can be reduced and minimizedOrganic active ingredientsIsotope introduction to heterocyclic compoundsDisease5-HT3 receptor
The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and / or pathways involving dopamine D1 / D2 receptor signaling systems, and / or the treatment of residual symptoms.
Owner:INTRA CELLULAR THERAPIES INC
Inhibitors of protein tyrosine kinase activity
This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
Owner:METHYLGENE
Methods for inhibiting lymphotoxin beta receptor signalling
This invention relates to compositions and methods comprising “lymphotoxin-β receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-β receptor extracellular domain that act as lymphotoxin-β receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-β receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-β receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-β receptor signalling is provided.
Owner:BIOGEN MA INC
Organic compounds
The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and / or pathways involving dopamine D2 receptor signaling systems.
Owner:INTRA CELLULAR THERAPIES INC
Organic compounds
ActiveUS20170183350A1To promote metabolismImproves in vitro hepatic microsome stabilityOrganic active ingredientsNervous disorderDisease5-HT3 receptor
The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and / or pathways involving dopamine D1 / D2 receptor signaling systems, and / or the treatment of residual symptoms.
Owner:INTRA CELLULAR THERAPIES INC
Novel Modulators
ActiveUS20110076284A1Reduces elevated HbA1c levelImproving impaired glucose toleranceMetabolism disorderDigestive systemAntiendomysial antibodiesMedicine
Owner:XOMA US
Methods and compositions for treating a subject for central nervous system (CNS) injury
ActiveUS20110224278A1Altered turnoverImprove plasticityBiocideNervous disorderGamma-Aminobutyric acidMedicine
Methods for treating a central nervous system (CNS) injury in a subject are provided. Aspects of the methods include administering to the subject an effective amount of gamma aminobutyric acid (GABA) receptor signaling inhibitor to treat the subject for the CNS injury. Also provided are compositions finding use in embodiments of the methods. Methods and compositions of the invention find use in the treatment of a variety of different CNS injuries, including but not limited to, treating a subject for CNS injury associated with the occurrence of stroke.
Owner:RGT UNIV OF CALIFORNIA
Inhibitors of VEGF receptor and HGF receptor signaling
ActiveUS20060074056A1Promote motilityPromote invasionBiocideOrganic chemistryVEGF receptorsHGF Receptor
The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions
Owner:METHYLGENE
Organic compounds
ActiveUS10077267B2Similar biological activityTo promote metabolismOrganic active ingredientsIsotope introduction to heterocyclic compoundsDisease5-HT4 receptor
The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and / or pathways involving dopamine D1 / D2 receptor signaling systems, and / or the treatment of residual symptoms.
Owner:INTRA CELLULAR THERAPIES INC
Inhibition of colony stimulating factor-1 receptor signaling for the treatment of brain cancer
InactiveUS20150119267A1Compound screeningApoptosis detectionAfter treatmentColony-stimulating factor
The present invention provides a method of screening brain tumor patients for treatment with inhibitor of CSF-1R, based on differential gene expression including adrenomeduUin (ADM), arginase 1 (ARG1), clotting factor F13A1, mannose receptor C type 1 (MRC1 / CD206), and protease inhibitor SERPINB2 after treatment with the inhibitor. Based on the same differential gene expression profile, the present invention also provides a method of screening a compound to treat brain cancer.
Owner:SLOAN KETTERING INST FOR CANCER RES
Organic compounds
ActiveUS20190231780A1Avoid side effectsInhibit the serotonin re-uptake transporterOrganic active ingredientsNervous disorderDisease5-HT4 receptor
The invention relates to particular substituted deuterated heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and / or pathways involving dopamine D1 / D2 receptor signaling systems, and / or the treatment of residual symptoms.
Owner:INTRA CELLULAR THERAPIES INC
Inhibitors of Protein Tyrosine Kinase Activity
This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions.
Owner:METHYLGENE
Specific chimeric antigen receptor against human HER 2 antigen, coding gene, expression vector and application
ActiveCN109824781AStrong killing specificityEnhance specific killing effectMammal material medical ingredientsFermentationSequence signalSingle-Chain Antibodies
The invention relates to a specific chimeric antigen receptor against a human HER 2 antigen, a coding gene, an expression vector and application. The chimeric antigen receptor against the human HER 2antigen comprises a human CD8 leader chimeric receptor signal peptide, a human HER2 single chain antibody, a human CD8 alpha hinge region, a human CD28 intracellular transmembrane region, a human 41BBintracellular region inducible co-stimulator and a human CD3 zeta intracellular signaling structure domain which are sequentially connected. The invention also provides the coding sequence, the recombinant expression vector and a construction method and application of the chimeric antigen receptor against the human HER2. The chimeric antigen receptor can be stably express on T lymphocytes, can specifically recognize and kill HER 2 positive tumor cells, improve the safety of treatment, and can be used for targeted therapy of tumors.
Owner:卢英
Antagonists of endothelial differentiation gene subfamily 3 (edg-3, s1p3) receptors for prevention and treatment of ocular disorders
InactiveUS20080025973A1Attenuating Smad signalingReduce signalingBiocideSenses disorderDiabetic retinopathyDisease
Antagonists of S1P3 (Edg-3) receptors are provided for attenuation of Smad signaling in a method of down-regulation of receptor signaling and downstream decreased production of connective tissue growth factor in ocular disorders involving CTGF accumulation. Ocular disorders involving inappropriate CTGF accumulation include ocular hypertension, glaucoma, glaucomatous retinopathy, optic neuropathy, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and ocular wound healing, for example. Such disorders are treated by administering antagonists of the present invention.
Owner:ALCON RES LTD
Methods for managing care of patients predisposed to progressive mitral valve diseases
InactiveUS20170058349A1Organic active ingredientsPeptide/protein ingredientsSerotonin transporterGenotyping
The present invention relates to methods for treating or preventing a mitral valve disease in a subject in need thereof, comprising administering to the subject an effective amount of a therapeutic agent. The therapeutic agent is capable of suppressing serotonin receptor signaling. The methods may be combined with a mitral valve surgery, serotonin transporter polymorphism genotyping, MV disease diagnosis, and / or an adjunct assay. Also provided are related medicaments, pharmaceutical compositions, and methods for preparing the medicaments.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Inhibitors of protein tyrosine kinase activity
ActiveUS20090264440A1Promote motilityPromote invasionBiocideSenses disorderKinase activityProtein-Tyrosine Kinases
This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
Owner:MIRATI THERAPEUTICS INC
Inhibitors of protein tyrosine kinase activity
InactiveUS20110077240A1Inhibit angiogenesisInhibit tyrosine kinase activityBiocideSenses disorderDiseaseKinase activity
This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions.
Owner:METHYLGENE
Transgenic animal
A transgenic rat containing in its genome a nucleotide sequence encoding a Ga subunit protein, which Ga protein subunit is uncoupled from regulation by Regulators of G-Protein Signaling (RGS) proteins, which Gx subunit protein is eventually the dominant-negative G188S mutant of Gax9, which nucleotide sequence is operatively associated with a neuron-specific expression control sequence, wherein the transgenic rat expresses the GA subunit protein in neural cells resulting in extended D-protein coupled receptor signaling mediated by the Ga subunit protein.
Owner:WYETH LLC
Organic compounds
ActiveUS20170037048A1Avoid side effectsStrong therapeutic activityOrganic active ingredientsIsotope introduction to heterocyclic compoundsDisease5-HT4 receptor
The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and / or pathways involving dopamine D1 / D2 receptor signaling systems, and / or the treatment of residual symptoms.
Owner:INTRA CELLULAR THERAPIES INC
A class of novel spiroheterocyclic compounds and their use as therapeutic agents
The present invention relates to general formula (I) spiroheterocyclic compound, its stereoisomer, enantiomer, tautomer or its mixture, or its pharmaceutically acceptable salt, solvate or prodrug, wherein ( II, k, j, P, Q, R1, R2 and R3) are as defined herein, which are useful for the treatment and / or prevention of diseases or conditions mediated by fibroblast growth factors and their receptor signaling pathways, such as cancer . Also disclosed are pharmaceutical compositions comprising the compounds and methods of using the compounds.
Owner:WENZHOU MEDICAL UNIV
Organic compounds
ActiveUS10688097B2Inhibit the serotonin re-uptake transporterModulate dopaminergic protein phosphorylationOrganic active ingredientsNervous disorderDiseaseSerotonin transporter
Owner:INTRA CELLULAR THERAPIES INC
Methods and compositions for treating tumor diseases
InactiveUS20100166747A1Reduced metabolic activitySymptoms improvedOrganic active ingredientsPeptide/protein ingredientsDiseaseNucleotide
The present invention provides, in part, methods for treating a tumor in a human subject comprising inhibiting IGF-1 receptor signaling, methods of determining whether a tumor is more or less likely to respond to such treatment, and compositions for practicing such methods. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.
Owner:AMGEN INC
Anti-IL-1beta monoclonal antibody and application thereof
The invention provides the technical field of antibody medicine, discloses a fully-humanized human anti-IL-1beta monoclonal antibody screened through the phage antibody library technology and prepared through the genetic engineering technology, and discloses a DNA molecule for encoding the monoclonal antibody, a DNA molecule expression carrier for encoding the monoclonal antibody, a host cell and application. The anti-IL-1beta monoclonal antibody can prevent bonding of human IL-1beta and human IL-1R. By means of bonding of IL-1beta, blocking of IL-1beta and a receptor signal channel of the IL-1beta, unnecessary IL-1beta initial induced heat transfer, amplified lymphocyte responses and stimulation acute stage responses can be reduced. The anti-IL-1beta monoclonal antibody can be used for detecting IL-1beta expressions and used for prevention and treatment of cryopyrin-associated periodic syndromes.
Owner:CHANGCHUN GENESCIENCE PHARM CO LTD
Synthesis Of Metabolically Stable Analgesics, Pain Medications And Other Agents
Disclosed are analgesic-related compositions and methods of using the compositions for modulation of analgesic receptor activity. The compositions and methods are useful for reducing pain, as well as for therapeutic intervention of addictions or other diseases or disorders amenable to treatment or prophylaxis by modulation of analgesic receptor signaling.
Owner:HUMAN BIOMOLECULAR RES INST
Methods and systems for determining personalized therapies
A method for generating an immune score, the method comprising the steps of: (i) determining a qualitative and / or quantitative assessment of tumor infiltrating lymphocytes in a sample; (ii) determining a qualitative and / or quantitative assessment of T-cell receptor signaling in the sample; (iii) determining a qualitative and / or quantitative assessment of mutation burden in the sample; (iv) generating, using a predictive algorithm, an immune score based on the determined qualitative and / or quantitative assessment of tumor infiltrating lymphocytes, the determined qualitative and / or quantitative assessment of T-cell receptor signaling, and the determined qualitative and / or quantitative assessment of mutation burden.
Owner:OMNISEQ INC
NOTCH mutations leading to increased receptor signaling
InactiveUS20100087358A1Enhanced signalBiocideCell receptors/surface-antigens/surface-determinantsCell growthEnzyme
The present invention is based upon the identification of regions within the NOTCH-1 receptor that, when mutated, lead to increase receptor signaling. The mutations are associated with uncontrolled cellular growth and this growth may be arrested using agents that interfere with NOTCH-1 activity, such as inhibitors of gamma-secretase. Assays for the NOTCH-1 mutations may be used diagnostically or as part of a treatment regimen for cancer patients.
Owner:DANA FARBER CANCER INST INC +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com